Clinical trials: High-Risk Non-Muscle-Invasive Bladder Cancer
Bladder Cancer
Sequential Combination Therapy in Bladder Cancer
A consecutive series of patients with High Risk Non-Muscle Invasive Bladder Cancer will be enrolled in several centres. The subjects will be assessed for eligibility at the screening visit (Visit 1) three weeks after…
- Trial name
- MITOBCG (NCT03790384)
- Testing
- Mitomycin
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera "Sant'Andrea"
Recurrence Free Survival, Bladder Cancer Recurrence
CRUCIAL-R Study : Cruciferous Vegetables Dietary Regimen in NMIBC
Emerging evidence highlights the importance of nutrition in modulating cancer-related pathways, suggesting that specific dietary patterns and food choices may influence cancer risk.
- Trial name
- CRUCIAL-R (NCT07391137)
- Testing
- Cruciferae intake diet, Habituary dietary regimen
- Where
- Italy
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- S. Andrea Hospital
Non-Muscle Invasive Bladder Cancer, HER2
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
This is a prospective, open, single-center clinical study of anti-HER2-ADC combined with PD-1 monoclonal antibody for bladder sparing treatment in non-muscular invasive bladder cancer (NMIBC) patients with HER2-expressing.
- Trial name
- NCT05957757
- Testing
- RC48, Tislelizumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital